Trust Guideline. for. Shared Care Guidelines for the Use of Leflunomide (Arava )
|
|
- Hollie Jones
- 7 years ago
- Views:
Transcription
1 A guideline recommended for use Trust Guideline for Shared Care Guidelines for the Use of Leflunomide (Arava ) In: By: For: East and North Herts NHS Trust (ENHT) East and North Herts PCT/ENHCCG Consultants in East and North Herts NHS Trust, GPs in ENHCCG and those elsewhere who share the care of patients with specialists at the ENHT, and Pharmacists Adult patients in East and North Herts NHS Trust and Primary Care Organisations (PCOs) Key Words: Written by: Supported by: Approved by: Leflunomide, rheumatoid arthritis, psoriatic arthritis, Arava Sharon Pearson (Rheumatology Specialist Nurse) Fiona Sinclair (General Practitioner and Chair of Herts Primary Care Medicines Management Committee [PCMMG]) TPC Sub-Committee Dr Spencer Ellis (Consultant Rheumatologist) Therapeutics Policy Committee Aide Viljoen (Chair) March 2013 Ratified by: Clinical Guidelines Steering Group Dr Diane Harvey (Chair) September 2015 Guideline issued: September 2013 To be reviewed before: September 2015 To be reviewed by: Guideline supersedes: Location of archived copy: Chief Pharmacist Not applicable Archive section of Pharmacy Intranet page and Clinical Governance U: Drive CGSG Guideline Registration No. 137 Version No. 01 Authors: Sharon Pearson and Fiona Sinclair Date of issue: September 2013 Page 1 of 11
2 Index Part One Shared Care Responsibilities Page No. 1. Hospital Specialist Responsibilities 3 2. General Practitioner Responsibilities 3 3. Patient Responsibilities 4 4. Contact Details 4 Part Two Supporting Information 1. Background 5 2. Indication 5 3. Dosage and Administration 5 4. Cost 5 5. Absolute Contra-indications 6 6. Pregnancy, Contraception and Breastfeeding 6 7. Monitoring 7 8. Common Side-Effects 7 9. Rare but Serious Side-Effects Drug Interactions Washout Regime 8 Appendix 1 9 Side Effects and Actions to be Taken Dissemination and Access This Guideline can only be considered valid when viewed via the East & North Hertfordshire NHS Trust Knowledge Centre. If this document is printed in hard copy, or saved at another location, you must check that it matches the version on the Knowledge Centre. Equality Impact Assessment This Guideline, and its impact upon equality, has been reviewed in line with the Trust s Equality Scheme and no detriment was identified. Authors: Sharon Pearson and Fiona Sinclair Date of issue: September 2013 Page 2 of 11
3 Part One - Shared Care Guideline for Leflunomide (Arava ) 1. Rheumatology Consultant / Rheumatology Specialist Nurse Responsibilities: Advise the patient and GP to arrange immunisation with one-off Pneumovax before starting leflunomide (Arava ), as immunisation is more effective prior to immunesuppression. Advise yearly flu vaccine with the first dose 2 weeks prior to starting immunesuppression if this coincides with the flu vaccination season (October to March). Supply the first month s prescription of leflunomide (Arava ). Write to the GP with a copy of the shared care guidelines requesting shared care after the patient has been commenced on leflunomide (Arava ). Provide regular clinic follow up review. Continue to monitor blood results and provide copies to the GPs. Alter the dose of leflunomide (Arava ), and other relevant medications, as required. Inform the GP of any changes in treatment. Provide advice during working hours via the Rheumatology Advice Line General Practitioner Responsibilities: Respond promptly to the request to enter into a shared care agreement If declining to enter into a shared care agreement explain why they are not in a position to take on shared care for leflunomide (Arava ). Notify the Rheumatology Department of any concerns about health or symptoms that might be related to leflunomide (Arava ) treatment. Follow the guidance in Appendix 1 Guideline re where urgent action is needed. Ensure leflunomide (Arava ) is entered in the electronic patient record, to aid checking for contraindications and drug interactions eg as a medication, even if the practice will not be issuing the prescriptions. Check blood test results prior to issuing prescriptions. Decline to issue a prescription if blood tests results are not available. Authors: Sharon Pearson and Fiona Sinclair Date of issue: September 2013 Page 3 of 11
4 3. Patient Responsibilities: Read the written information provided at the initial visit, and seek clarification of any points of the treatment that are unclear. Inform the specialist, GP or community pharmacist dispensing their prescriptions of any other medication being taken including over-the-counter medication. Report any concerns, adverse effects or warning symptoms to the specialist or GP whilst taking leflunomide (Arava ). Use reliable contraception during leflunomide (Arava ) treatment if patient or partner is of child-bearing age. Take up the offer of immunisation as advised by the specialist and GP, or actively decline. Take the leflunomide (Arava ) as prescribed 4. Contact Details: Specialist Designation Contact number Dr Binder Consultant Rheumatologist Dr Axon Consultant Rheumatologist Dr Ellis Consultant Rheumatologist Dr Wijeyekoon Consultant Rheumatologist Rheumatology advice-line Rheumatology Nurse Specialist Annual Review advice-line Rheumatology Nurse Practitioner Authors: Sharon Pearson and Fiona Sinclair Date of issue: September 2013 Page 4 of 11
5 Part Two Supporting Information 1. BACKGROUND Rheumatoid Arthritis (1,2,3) Rheumatoid arthritis (RA) is the most common chronic inflammatory joint disease affecting 0.5 1% of the population. It is believed that RA is triggered by exposure of an immunogenetically susceptible host to an arthritogenic antigen. A continuing auto-immune reaction ultimately leads to joint destruction. The present aim of treatment is to control joint inflammation as early as possible after diagnosis. This should lead to pain reduction and maintain the range of joint movement, minimise loss of function, prevent deformity and keep patients mobile and independent. Several factors have influenced the change in practice, which advocates the earlier use of disease modifying antirheumatic drugs (DMARDs). The rate of occurrence of bony erosions is greatest during the first two years of RA and there is evidence that earlier use of DMARDs slows radiological progression and improves function. The toxicity of DMARDs is similar to NSAIDs, particularly during the early stages of RA when patients general health is good and newer DMARDs eg methotrexate, are less toxic and more effective than those previously available. 2. Indications Leflunomide (Arava ) is a disease-modifying anti-arthritic drug (DMARD) licensed for the use in treatment of adult patients with moderate to severe rheumatoid arthritis and active psoriatic arthritis. Leflunomide (Arava ) is an immunomodulatory agent used for patients who have failed on other available DMARDs including sulphasalazine and methotrexate. It is known to retard structural damage and provide early clinical benefit. Leflunomide can be used in combination with methotrexate, with extra vigilance in the first few months, blood monitoring 4 weekly, due to the increased risk of hepatic reactions and bone marrow toxicity. Leflunomide has a good safety record with few serious adverse effects. Most side effects occur within the first three months. Leflunomide is immunosuppressive and can increase the risk of opportunistic and other infections. Leflunomide can take up to twelve weeks to take effect and even six months for full benefit. Due to the long half-life there is no point in stopping therapy during inter-current infection unless sepsis is identified, when the washout procedure may be advised. 3. Dosage and Administration: (4) 10 mg to 20 mg once daily (orally) with or after food. 4. Cost for 30 days: (6) (Prices from Drug Tariff March 2013) Leflunomide 10 mg (white) 30 tablet pack mg (yellow) 30 tablet pack Authors: Sharon Pearson and Fiona Sinclair Date of issue: September 2013 Page 5 of 11
6 5. Absolute Contra-indications: (4) Significant immune, hepatic or renal impairment. On-going infections. Use with caution in patients with a history of TB. Not recommended for use in patients under 18 years Pregnancy and breast feeding. The active metabolite is teratogenic. 6. Pregnancy, Contraception and Breastfeeding Exclude pregnancy and breast feeding prior to commencing treatment. Effective contraception is essential for both men and women during treatment and for at least two years after treatment in women and three months in men if the washout procedure is not performed 5 Leflunomide is teratogenic and there is a theoretical risk of sperm mutation in males. Women planning to have children should either discontinue leflunomide 2 years prior to conception or have a rapid removal of its active metabolite following the washout procedure. Leflunomide is excreted into breast milk in low concentrations and should be avoided. Blood concentrations should be checked prior to pl anning pr egnancy especiall y if w ithin 2 year s of st opping leflunomide or follow ing w ash out. An y pregnancy w ithin 2 years of discontinuation of leflunomide should be discussed w ith rheumatologist if drug w ashout has not been performed. Notif y pharmaceut ical company in the event of pr egnancy w hile on leflunomide. Authors: Sharon Pearson and Fiona Sinclair Date of issue: September 2013 Page 6 of 11
7 7. Monitoring: British Society for Rheumatology (BSR) guidelines: NB These differ from those in the Summary of Product Characteristics 4 a. Baseline assessment b. On-going Monitoring Additional monitoring (for disease activity) FBC, U&E, LFTs. Pregnancy test for women child bearing age. Blood pressure: If >140/90 on two consecutive readings, 2 weeks apart, treat hypertension in line with NICE guidance before commencing the drug. Weight: to allow assessment of weight loss as this may be attributable to leflunomide. These tests will be carried out by the initiating hospital specialist. FBC, LFTs every month for 6 months and, if stable, 2 monthly thereafter. Blood checks should be continued long-term, at least once a month, if co-prescribed with another immunosuppressant or potentially hepatotoxic agent such as methotrexate. U&Es 6-12 monthly (more frequently if there is any reason to suspect deteriorating renal function) Blood pressure and weight should be checked at each monitoring visit within secondary care. ESR and/or CRP every three months 8. Common Side-Effects: (See Appendix 1 for more details) If a dose reduction is indicated below, contact the rheumatology advice line to discuss. Since leflunomide has a very long half-life, have a low threshold for deferring treatment until advice is received. Blood pressure: can cause mild increase especially with pre-existing hypertension. If >140/90 treat in line with NICE guidance. Gastrointestinal: o Diarrhoea - most common side effect. Usually self-limiting, but if persistent discuss with Rheumatology Consultant to consider reducing leflunomide dose and/or using loperamide. o Nausea - usually self-limiting but if persists Rheumatology Team will reduce leflunomide dose or advise trying an antiemetic. Rash: Usually mild. Try reducing leflunomide dose but if it persists, stop the drug. Mild elevation of LFT s (1-3 fold rise in ALT/AST whichever is included in LFT bundle): reduce leflunomide dose; (20 mg to 10 mg daily or 10 mg to defer) according to liver function abnormality. If liver function abnormality persists, discontinue treatment and consider washout procedure. Alopecia: Usually mild and self-limiting. Dose reduction may be of benefit. Other common side-effects include: anorexia, mouth ulceration, weight loss (usually insignificant), headache, dizziness, tenosynovitis, eczema and dry skin. Authors: Sharon Pearson and Fiona Sinclair Date of issue: September 2013 Page 7 of 11
8 9. Rare but Serious Side-Effects Stop treatment and seek advice via Rheumatology Advice Line and/or admit as an emergency depending on the patient s condition in the case of: Severe rash Bone marrow aplasia Severe hepatic toxicity eg Stevens Johnson syndrome WCC <3.5 x 10 9 /L, Neutrophils <2 x 10 9 /L, Platelets <150 x 10 9 /L >3 fold rise in ALT/AST Severe anaphylactic / anaphylactoid reaction Weight loss Breathlessness Progressive Mulitfocal Leukoencephalopathy (PML) if >10% with no cause identified Worsening shortness of breath (SOB) Very rare complication of all immunesuppressive agents (see BNF) 10. Drug interactions: Colestyramine reduces level of active metabolite of leflunomide, however it can be used as part of a washout procedure if required. Warfarin check INR after any change in leflunomide, as INR may be increased by leflunomide Phenytoin check levels, as these may be increased by leflunomide. Consider a reduction in tolbutamide and/or blood glucose monitoring due to risk of hypoglycaemia. Vaccination with live vaccines is contraindicated (Influenza and Pneumococcal vaccines are not live and are recommended). Increased risk of side-effects with recent or concomitant use of hepatotoxic drugs or when leflunomide is followed by such drugs without a washout period. Alcohol - should be limited to fewer than 10 units a week due to an increased risk of hepatotoxicity. Use of concomitant methotrexate may cause increased side-effects. 11. Washout Regime: (4) In the event of severe side-effects, or if pregnancy is desired, a washout can be performed using colestyramine 8g TDS OR activated powdered charcoal 50g QDS; each for 11 days. See current BNF for more information. Authors: Sharon Pearson and Fiona Sinclair Date of issue: September 2013 Page 8 of 11
9 Appendix 1 Side Effects and Actions to be Taken Authors: Sharon Pearson and Fiona Sinclair Date of issue: September 2013 Page 9 of 11
10 WBC<3.5 x 10 9 /L Side Effect/s Neutrophils<2.0 x 10 9 /L Platelets<150 x 10 9 /L AST and/or ALT between two and three times the upper limit of reference range AST and/or ALT more than three times the upper limit of reference range Rash or itch Hair loss Abnormal bruising or severe sore throat Hypertension Headache GI upset (nausea, diarrhoea) Weight loss Breathlessness Actions to be taken Withhold until discussed with Specialist Team. Withhold until discussed with Specialist Team. Withhold until discussed with Specialist Team. If the current dose is more than 10mg daily reduce the dose to 10mg daily and recheck weekly until normalised. If the AST & ALT is returning to normal, leave on 10mg a day. If LFTs remain elevated (levels dependent) withdraw the drug and discuss with the specialist team. Recheck LFTs within 72 hours, if still more than three times the reference range: stop drug, discuss with the specialist team and consider washout. Consider dosage reduction with or without antihistamines; if severe, stop drug, discuss with the specialist team and consider washout. Consider dosage reduction; if severe, stop drug, discuss with the specialist team and consider washout. Check FBC immediately and withhold until results are available. If BP>140/90 treat in line with NICE guidance. If BP remains uncontrolled, stop leflunomide and consider washout. If severe, consider dosage reduction. If headaches persist, stop and consider washout. If loading dose has been used, give symptomatic treatment. If steady state has been reached, give symptomatic treatment and consider dosage reduction. If symptoms are severe or persistent, stop and consider washout. Monitor carefully. If >10% weight loss with no other cause identified, reduce dosage or stop and consider washout. If increasing shortness of breath occurs, stop leflunomide and consider washout. Authors: Sharon Pearson and Fiona Sinclair Date of issue: September 2013 Page 10 of 11
11 12. References 1) British Society for Rheumatology and British Health Professionals in Rheumatology guidelines for the management of Rheumatoid arthritis (after 2 years) BSR/BHPR ) BSR/BHPR guidelines for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists, Rheumatology ) Use of Oral Methotrexate Shared Care Guidelines for Adults, ) Leflunomide. Summary of Product Characteristics. Sanofi ) British National Formulary September ) Drug Tariff March 2013 Resources: Authors: Sharon Pearson and Fiona Sinclair Date of issue: September 2013 Page 11 of 11
LEFLUNOMIDE (Adults)
Shared Care Guideline DRUG: Introduction: LEFLUNOMIDE (Adults) Indication: Disease modifying drug for rheumatoid arthritis and psoriatic arthritis Licensing Information: Disease modifying drug for active
More informationShared Care Guideline for the use of Leflunomide for Rheumatoid Arthritis
Shared Care Guideline for the use of Leflunomide for Rheumatoid Section 1: Agreement for transfer of prescribing to GP Please sign this form and return it to the named consultant if you are willing to
More informationLeflunomide Leflunomide
Drug information Leflunomide Leflunomide This leaflet provides information on leflunomide and will answer any questions you have about the treatment. Arthritis Research UK produce and print our booklets
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
More informationEMEA PUBLIC STATEMENT ON LEFLUNOMIDE (ARAVA) - SEVERE AND SERIOUS HEPATIC REACTIONS -
The European Agency for the Evaluation of Medicinal Products Post-authorisation evaluation of medicines for human use London, 12 March 2001 Doc. Ref: EMEA/H/5611/01/en EMEA PUBLIC STATEMENT ON LEFLUNOMIDE
More informationShared care protocol for the management of patients with Rheumatoid Arthritis treated with disease modifying antirheumatic drugs (DMARDs)
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared care protocol for the management of patients with Rheumatoid Arthritis treated with disease modifying antirheumatic drugs (DMARDs)
More information5.07.09. Aubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)
More informationRheumatoid Arthritis monitoring of DMARDs
www.bpac.org.nz keyword: DMARDS Rheumatoid Arthritis monitoring of DMARDs Key reviewers: Professor John Highton, Head of Section, Department of Medical and Surgical Sciences, Dunedin School of Medicine,
More informationAdjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationRheumatoid Arthritis. GP workshop 15 January 2011
Rheumatoid Arthritis GP workshop 15 January 2011 Case 1 A 72 year old Malay woman with RA comes for routine follow up. She feels generally unwell in the last 5 days. Appetite is fair. Her joints are fine.
More informationRivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationDabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationTeriflunomide (Aubagio) 14mg once daily tablet
Teriflunomide (Aubagio) 14mg once daily tablet Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Teriflunomide. The decision
More informationabc Trust Guideline for Use of Oral Methotrexate, Shared Care Guideline for Adults
Trust Guideline for abc Use of Oral Methotrexate, Shared Care Guideline for Adults A guideline recommended for use In: East and North Herts NHS Trust East and North Herts PCT By: Consultants in East and
More informationMETHOTREXATE TREATMENT
METHOTREXATE TREATMENT This leaflet has been prepared to support information given to you as part of your discussions with the doctor, nurse or pharmacist before you start treatment with oral methotrexate.
More informationMETHOTREXATE Rheumatoid arthritis, Psoriasis, Crohn s Disease & Ulcerative Colitis DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AND FILED IN NOTES
NHS ONEL and BHRuT NHS Trust Shared Care Guidelines METHOTREXATE Rheumatoid arthritis, Psoriasis, Crohn s Disease & Ulcerative Colitis DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AND FILED IN NOTES
More informationMethotrexate treatment
Methotrexate treatment Oral methotrexate pre-treatment patient information leaflet This leaflet has been prepared to support information given to you as part of your discussions with the doctor, nurse
More informationRivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)
Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE) Amber Drug Level 2 Leeds We have started your patient on rivaroxaban for the treatment of provoked VTE (deep
More informationDonepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )
Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) ESCA: For the treatment of Alzheimer s disease. SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR
More informationRheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion
Rheumatoid Arthritis Robert L. Talbert, Pharm.D., FCCP, BCPS University of Texas at Austin College of Pharmacy University of Texas Health Science Center at San Antonio Outline Clinical evaluation New treatment
More informationEastern Health MS Service. Tysabri Therapy. Information for People with MS and their Families
Eastern Health MS Service Tysabri Therapy Information for People with MS and their Families The Eastern Health MS Service has developed this information for you as a guide through what will happen to you
More informationMedicines for Psoriatic Arthritis. A Review of the Research for Adults
Medicines for Psoriatic Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this information is right for you if: Your doctor* has told you that you have psoriatic (pronounced
More informationRituximab. Drug information Rituximab. This leaflet provides information on rituximab and will answer any questions you have about the treatment.
Drug information Rituximab Rituximab This leaflet provides information on rituximab and will answer any questions you have about the treatment. Arthritis Research UK produce and print our booklets entirely
More informationMaintenance of abstinence in alcohol dependence
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
More informationNaltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
More informationLung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Indication: In combination with docetaxel in locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma
More informationEvidence-based Management of Rheumatoid Arthritis (2009)
CPLD reviews its distance learning programmes every twelve months to ensure currency. This update has been produced by an expert and should be read in conjunction with the Evidencebased Management of distance
More informationShared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia
Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Version: 3.0 Ratified by: Medicines Committee Date ratified: 16 th November 2011 Name of originator/author: James
More informationTeriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).
Page 1 of 10 ANALYTE NAME AND STRUCTURE TERIFLUNOMIDE Teriflunomide TRADE NAME Aubagio CATEGORY Antimetabolite TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND sclerosis. The
More informationpatient group direction
DICLOFENAC v01 1/8 DICLOFENAC PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner
More informationPatient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust.
Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust. This Patient Group Direction (PGD) has been written
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationPatient Information Leaflet
Patient Information Leaflet METHOTREXATE We hope this fact sheet will provide you with some information about Methotrexate and answer some of the questions you may have. Methotrexate is available in tablet
More informationCICLOSPORIN. What are the aims of this leaflet?
CICLOSPORIN What are the aims of this leaflet? This leaflet has been written to help you understand more about ciclosporin. It tells you what it is, how it works, how it is used to treat skin conditions,
More informationInfl ectra for rheumatoid arthritis
Infl ectra for rheumatoid arthritis Some important information to get you started with your treatment This booklet is intended only for use by patients who have been prescribed Inflectra. Introduction
More informationLung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)
Indication: NICE TA181 First line treatment option in advanced or metastatic non-squamous NSCLC (histology confirmed as adenocarcinoma or large cell carcinoma) Performance status 0-1 Regimen details: Pemetrexed
More informationORAL MEDICATIONS FOR MS! Gilenya and Aubagio
ORAL MEDICATIONS FOR MS! Gilenya and Aubagio Champions against MS 4/20/13 Alexandra Goodyear, MD Stanford University Oral Medications Since 2010, 3 new oral medications for MS: Gilenya 2010 Aubagio 2012
More informationSymptoms ongoing for 6/12, initially intermittent in nature.
Rheumatoid Arthritis Case Study INTRODUCTION Each student will have watched the relevant MDT member carrying out their initial assessment on the same newly diagnosed Rheumatoid Arthritis patient. Videos
More information**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011
Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both
More informationThere is a risk of renal impairment in dehydrated children and adolescents.
PACKAGE LEAFLET: INFORMATION FOR THE USER MELFEN 200mg FILM-COATED TABLETS MELFEN 400mg FILM-COATED TABLETS Ibuprofen Read all of this leaflet carefully before you start taking this medicine because it
More informationMANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol)
MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol) 1. Hepatotoxicity: In Active TB Disease a. Background: 1. Among the 4 standard anti-tb drugs,
More informationDrugs for Alcohol Dependence: Clinical Guidance and Three Way Agreement
Drugs for Alcohol Dependence: Clinical Guidance and Three Way Agreement for County Durham In partnership with the GP, the client, and the County Durham Drug and Alcohol Service December 2015 Version 1.0
More informationThis regimen has low emetogenic potential refer to local protocol None required routinely. Baseline results valid for 7 days. Results valid for 72 hrs
Regimen : Ipilimumab for Advanced Melanoma ICD10 code Codes pre-fixed with C43. Indication Regimen detail Ipilimumab is recommended as an option for treating advanced (unresectable or metastatic) melanoma
More informationMS Treatments Aubagio TM
1 MSology Essentials Series Aubagio TM (teriflunomide) Developed by MSology with the invaluable assistance of multiple sclerosis nurse advisors: Bonnie Blain Central Alberta MS Clinic, Red Deer, Alberta
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More information2. Characteristics of staff Qualifications required. Additional requirements. Continued education & training requirements
Patient Group Direction The supply of Azithromycin 1g as a single dose by accredited Community Pharmacists to patients in receipt of a positive test result to Chlamydia trachomatis, and treatment of their
More informationA guide to the accelerated elimination procedure
A guide to the accelerated elimination procedure Prescribing information and information on adverse event reporting can be found on the last page. What is the accelerated elimination procedure? An accelerated
More informationRheumatology. Rheumatoid Arthritis
Rheumatology Rheumatoid Arthritis The Rheumatology service specialises in the diagnosis and treatment of diseases affecting the musculoskeletal system. Other than providing inpatient and outpatient consultation,
More information3. The near patient testing service is designed to be one in which:
National enhanced service Provision of near-patient testing Introduction 1. All practices are expected to provide essential and those additional services they are contracted to provide to all their patients.
More informationMedicines for Rheumatoid. Arthritis. A Review of the Research for Adults
Medicines for Rheumatoid Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this summary is for you if: Your doctor* has told you that you have rheumatoid (pronounced
More informationMELATONIN FOR SLEEP DISORDERS IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS SHARED CARE GUIDELINES
MELATONIN FOR SLEEP DISORDERS IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS SHARED CARE GUIDELINES Version control: Version Date Main changes/comments V1 4 June 2013 First draft circulated
More informationRheumatoid Arthritis Medicines. A Guide for Adults
Rheumatoid Arthritis Medicines A Guide for Adults Fast Facts Medicines for rheumatoid arthritis (RA) can slow down the disease and reduce damage to joints. They can relieve pain and make it easier to do
More informationMEDICATION GUIDE STELARA
MEDICATION GUIDE STELARA (stel ar a) (ustekinumab) Injection What is the most important information I should know about STELARA? STELARA is a medicine that affects your immune system. STELARA can increase
More informationThe management of rheumatoid arthritis
Medical management of rheumatoid arthritis Peter Jones Correspondence to: peter.jones@qehealth.co.nz The management of rheumatoid arthritis has changed in the last 10 years. Back then, a patient who awoke
More informationSummary of the risk management plan (RMP) for Otezla (apremilast)
EMA/741412/2014 Summary of the risk management plan (RMP) for Otezla (apremilast) This is a summary of the risk management plan (RMP) for Otezla, which details the measures to be taken in order to ensure
More informationOxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients
Oxford University Hospitals NHS Trust Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis Information for patients page 2 What is Natalizumab and what is it used for? Natalizumab is an
More informationDrug Treatment Information for patients with Inflammatory Bowel Disease. Infliximab
Drug Treatment Information for patients with Inflammatory Bowel Disease Infliximab Improving life for people affected by Colitis and Crohn s Disease National Association For Colitis and Crohn s Disease
More informationTreatment of diseases affecting the kidney using steroids
Treatment of diseases affecting the kidney using steroids Hope Building Renal 0161 206 5223 All Rights Reserved 2015. Document for issue as handout. This information has been written by the medical and
More informationPrescribing Framework for Donepezil in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Donepezil in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP
More informationAtrial Fibrillation and Anticoagulants
York Teaching Hospital NHS Foundation Trust Atrial Fibrillation and Anticoagulants A guide to your diagnosis and treatment Information for patients, relatives and carers For more information, please contact:
More informationHow long will it take to work? You may begin to feel better within a few days or it may take up to six weeks after your first treatment session.
Crohn's and Colitis UK Drug Treatment Information Improving life for people affected by inflammatory bowel diseases Infliximab This information leaflet aims to answer common questions you may have if you
More informationParacetamol apollo +9191 46 950 950. Paracetamol apollo +9191 46 950 950. Paracetamol
Paracetamol apollo +9191 46 950 950 Paracetamol apollo +9191 46 950 950 Paracetamol CAS Number : 103-90-2 Molecular Weight : 151.17 g/mol Molecular Formula : C8H9NO2 Systematic (IUPAC) : N-(4- hydroxyphenyl)ethanamide
More informationRheumatic Diseases 2005
COLLECTED REPORTS ON THE Rheumatic Diseases 2005 SERIES 4 (REVISED) Published by the Arthritis Research Campaign (arc) Editors: Ade O Adebajo FRCP(Glasgow) D John Dickson MBChB FRCP(Glasgow) FRCP(London)
More informationMorgan Schultz 1, Stephanie Keeling 2, Steven Katz 2, Walter Maksymowych 2, Dean Eurich 3, Jill Hall 1 1
Morgan Schultz 1, Stephanie Keeling 2, Steven Katz 2, Walter Maksymowych 2, Dean Eurich 3, Jill Hall 1 1 Faculty of Pharmacy and Pharmaceutical Sciences, 2 Faciluty of Medicine and Dentistry, 3 School
More informationswine flu vaccination:
swine flu vaccination: what you need to know Flu. Protect yourself and others. Contents What is swine flu?............... 3 About the swine flu vaccine....... 4 What else do I need to know?...... 8 What
More informationBreast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail
Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail Indication: Neoadjuvant or adjuvant therapy for elderly and frail patients with breast
More informationNCCP Chemotherapy Protocol. Afatinib Monotherapy
Afatinib Monotherapy INDICATIONS FOR USE: INDICATION Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
More informationIMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products
Dear Healthcare Provider: Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) has been mandated by the FDA (Food and Drug Administration) due to postmarketing reports showing that exposure to
More informationAllopurinol Allopurinol
Drug information Allopurinol Allopurinol This leaflet provides information on allopurinol and will answer any questions you have about the treatment. Arthritis Research UK produce and print our booklets
More informationPOAC CLINICAL GUIDELINE
POAC CLINICAL GUIDELINE Acute Pylonephritis DIAGNOSIS COMPLICATED PYELONEPHRITIS EXCLUSION CRITERIA: Male Known or suspected renal impairment (egfr < 60) Abnormality of renal tract Known or suspected renal
More informationAcetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD)
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Acetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD) Version: 3 Date Approved: June 2011 Review
More informationWarfarin therapy for stroke patients with atrial fibrillation
Warfarin therapy for stroke patients with atrial fibrillation Delivering the best in care UHB is a no smoking Trust To see all of our current patient information leaflets please visit www.uhb.nhs.uk/patient-information-leaflets.htm
More informationPsoriasis and Psoriatic Arthritis Alliance
Psoriasis and Psoriatic Arthritis Alliance A principal source of information on psoriasis and psoriatic arthritis ) Treatments for Psoriatic Arthritis overview Although psoriatic arthritis is a chronic
More informationA patient and public guide to the National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis
A patient and public guide to the National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis 1st Annual Report 2015 (Data collection: 1 February 2014 30 April 2015) 2 Contents Background Who
More informationGuideline for the use of Biological Therapies in the Treatment of Psoriasis
1 Date of Production: March1 st 2011 Date of 1 st review: July 10 th 2015 Date for next review: March1 st 2018 Local Contact Dermatology Consultant Shanti Ayob Patient group to which this applies: Patients
More informationCare Pathway for the Administration of Intravenous Iron Sucrose (Venofer )
Departments of Haematology, Nephrology and Pharmacy Care Pathway for the Administration of Intravenous Iron Sucrose (Venofer ) [Care Pathway Review Date] Guidance for use This Care Pathway is intended
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK ACAMPROSATE CALCIUM (Campral EC) for alcohol abstinence ESCA: Adjunct in the treatment of chronic alcohol dependence (under
More informationMEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate
MEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate Read this Medication Guide before you start receiving mitoxantrone and each time you receive mitoxantrone. There may be new information.
More informationBCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )
BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT ) Protocol Code Tumour Group Contact Physician UGIPNSUNI Gastrointestinal Dr. Hagen
More informationNHS FORTH VALLEY Guidelines for use of high dose Intravenous Esomeprazole in Adults (Previously called the Hong Kong Protocol)
NHS FORTH VALLEY Guidelines for use of high dose Intravenous Esomeprazole in Adults (Previously called the Hong Kong Protocol) Date of First Issue 10/05/2010 Approved 16/06/2010 Current Issue Date 18/11/2015
More informationRHEUMATOID ARTHRITIS. Dr Bruce Kirkham Rheumatology Clinical Lead
RHEUMATOID ARTHRITIS Dr Bruce Kirkham Rheumatology Clinical Lead RHEUMATOID ARTHRITIS (RA) RA is a common disease: 0.8 per cent of the population RA more common in females: female to male ratio 3:1 RA
More informationEnoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants
Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants Traffic light classification- Amber 2 Information sheet for Primary Care Prescribers Relevant Licensed Indications
More informationIntravenous Methyl Prednisolone in Multiple Sclerosis
Intravenous Methyl Prednisolone in Multiple Sclerosis Exceptional healthcare, personally delivered Relapse management in multiple sclerosis Relapses in multiple sclerosis (MS) are common and caused by
More informationPATIENT INFORMATION LEAFLET. CEFALEXIN 250 mg AND 500 mg CAPSULES CEFALEXIN
PATIENT INFORMATION LEAFLET CEFALEXIN 250 mg AND 500 mg CAPSULES CEFALEXIN Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again.
More informationWest of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021)
West of Scotland Cancer Network Chemotherapy Protocol Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) Indication Palliative chemotherapy for malignant mesothelioma of the pleura Eligibility
More informationRheumatoid Arthritis www.arthritis.org.nz
Rheumatoid Arthritis www.arthritis.org.nz Did you know? RA is the second most common form of arthritis Approximately 40,000 New Zealanders have RA RA can occur at any age, but most often appears between
More informationMultiple sclerosis disease-modifying drugs second line treatments
Great Ormond Street Hospital for Children NHS Foundation Trust: Information for Families Multiple sclerosis disease-modifying drugs second line treatments The following information should be read in conjunction
More informationMedication Guide Enbrel (en-brel) (etanercept)
Medication Guide Enbrel (en-brel) (etanercept) Read the Medication Guide that comes with Enbrel before you start using it and each time you get a refill. There may be new information. This Medication Guide
More informationGilenya. Exceptional healthcare, personally delivered
Gilenya Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Gilenya. The decision to start this form of treatment can be difficult.
More informationTravel to Africa 2005. David V. Diamond, MD MIT Medical Department
Travel to Africa 2005 David V. Diamond, MD MIT Medical Department 1 General Advice: Overall risks are low for diseases other than Traveler's diarrhea Preventative measures to avoid exposure to mosquito
More informationImmune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association
Immune modulation in rheumatology Geoff McColl University of Melbourne/Australian Rheumatology Association A traditional start to a presentation on biological agents in rheumatic disease is Plasma cell
More informationSWINE FLU: FROM CONTAINMENT TO TREATMENT
SWINE FLU: FROM CONTAINMENT TO TREATMENT SWINE FLU: FROM CONTAINMENT TO TREATMENT INTRODUCTION As Swine Flu spreads and more people start to catch it, it makes sense to move from intensive efforts to contain
More informationBreast Pathway Group AC (Doxorubicin / Cyclophosphamide) in Early Breast Cancer
Breast Pathway Group AC (Doxorubicin / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment of breast cancer Regimen details: Doxorubicin 60mg/m 2 IV Day 1 Cyclophosphamide
More informationDr Sarah Levy Consultant Rheumatology Croydon University Hospital
Dr Sarah Levy Consultant Rheumatology Croydon University Hospital Contents Definition/ epidemiology Diagnosis Importance of early diagnosis/ treatment Guidelines Evidence based treatment protocol Current
More informationDISEASE MODIFYING THERAPY CARE PATHWAY. Multiple Sclerosis Service
DISEASE MODIFYING THERAPY CARE PATHWAY Multiple Sclerosis Service CONTENTS Disease modifying therapy care pathway ABN guidelines Appendix 1 MS Service DMT Sheet Appendix 2 Who to contact info Appendix
More informationMANAGEMENT OF TUBERCULOSIS
MANAGEMENT OF TUBERCULOSIS Dean B. Ellithorpe, M.D. Clinical Professor of Medicine Section of Pulmonary Diseases, Critical Care and Environmental Medicine Tulane University School of Medicine INTRODUCTION
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Dalacin C 150 mg Capsules. clindamycin hydrochloride. Dalacin C 150mg Capsules clindamycin hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER PFIZER Dalacin C 150 mg Capsules clindamycin hydrochloride Dalacin C 150mg Capsules clindamycin hydrochloride PFIZER Read all of this leaflet carefully before
More informationProfessor Andrew Wright,
Professor Andrew Wright, Systemic treatments are drugs taken as tablets or injections that travel through the bloodstream, dampening down the immune system to reach and treat eczema all over the body.
More informationZOVIRAX Cold Sore Cream
Data Sheet ZOVIRAX Cold Sore Cream Aciclovir 5% w/w Presentation Topical cream Indications ZOVIRAX Cold Sore Cream is indicated for the treatment of Herpes simplex virus infections of the lips and face
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr NUCALA [new-ka la] mepolizumab lyophilized powder for subcutaneous injection Read this carefully before you start
More information